{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T17:55:14Z","timestamp":1778954114166,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ejca.2020.03.016","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T06:44:44Z","timestamp":1588661084000},"page":"207-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Adjuvant immunotherapy: the sting in the tail"],"prefix":"10.1016","volume":"132","author":[{"given":"Claire E.","family":"Higham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktoria","family":"Chatzimavridou-Grigoriadou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl T.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0146-3835","authenticated-orcid":false,"given":"Peter J.","family":"Trainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.03.016_bib1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.03.016_bib2","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2020.03.016_bib3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1200\/JCO.19.01381","article-title":"Phase III study of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American intergroup E1609","volume":"38","author":"Tarhini","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.03.016_bib4","first-page":"JCO1902988","article-title":"Another victory for immune checkpoint blockade in melanoma: adjuvant ipilimumab over interferon","author":"Betof Warner","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.03.016_bib5","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.03.016_bib6","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.03.016_bib7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejca.2019.05.020","article-title":"Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325\/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma","volume":"116","author":"Eggermont","year":"2019","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.03.016_bib8","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(17)30703-1","article-title":"Hypothyroidism","volume":"390","author":"Chaker","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.03.016_bib9","doi-asserted-by":"crossref","first-page":"l4892","DOI":"10.1136\/bmj.l4892","article-title":"Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study","volume":"366","author":"Thayakaran","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2020.03.016_bib10","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2020.03.016_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ejca.2020.03.016_bib12","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1210\/jc.2006-0076","article-title":"Premature mortality in patients with Addison's disease: a population-based study","volume":"91","author":"Bergthorsdottir","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ejca.2020.03.016_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/cen.13609","article-title":"Mortality data from the European adrenal insufficiency registry-patient characterization and associations","volume":"89","author":"Quinkler","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"6","key":"10.1016\/j.ejca.2020.03.016_bib14","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/andr.262","article-title":"Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study","volume":"2","author":"Gastrelli","year":"2014","journal-title":"Andrology"},{"issue":"Suppl3","key":"10.1016\/j.ejca.2020.03.016_bib15","first-page":"7","article-title":"Use of exogenous gonadotropins in anovulatory women: a technical bulletin","volume":"90","year":"2008","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejca.2020.03.016_bib16","series-title":"Trends and figures: 2010- 2016. Human fertilisation and embryology authority","year":"2018"},{"key":"10.1016\/j.ejca.2020.03.016_bib17","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dme.14050","article-title":"Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis","volume":"36","author":"Akturk","year":"2019","journal-title":"Diabet Med"},{"key":"10.1016\/j.ejca.2020.03.016_bib18","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"376","author":"Rawshani","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2020.03.016_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011501","article-title":"Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method","volume":"5","author":"Tao","year":"2010","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.ejca.2020.03.016_bib20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1210\/js.2016-1064","article-title":"Health care burden in patients with adrenal insufficiency","volume":"1","author":"Gunnarsson","year":"2017","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ejca.2020.03.016_bib21","article-title":"Prognostic and predictive value of immune-related adverse events among stage III melanoma patients included in the EORTC 1325\/KEYNOTE-054 pembrolizumab vs placebo trial","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492030157X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492030157X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:28:31Z","timestamp":1760732911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492030157X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":21,"alternative-id":["S095980492030157X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.03.016","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant immunotherapy: the sting in the tail","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}